Eplerenon: A randomized, double-masked, placebo controlled study of the beneficial effects of eplerenone on central serous chorioretinopathy

Central serous chorioretinopathy (CSC) is supposedly the fourth most common non-surgical retinopathy after age-related macular degeneration, diabetic retinopathy and branch retinal vein occlusion. Aim of this study is to compare the treatment effects of eplerenone, an aldosterone antagonist versus placebo in patients with acute or chronic CSC with an untreated observational period of at least 2 months. If there is no sign of clinical improvement within the first 16 weeks after the onset of symptoms, patients will be offered half-fluence PDT.